Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483362 | 0.82 | CA2 (0.34) | CA2 | |
| SCHEMBL14931283 | 0.81 | CA2 (0.34) | CA2 | |
| SCHEMBL3483248 | 0.77 | CA2 (0.32) | CA2 | |
| SCHEMBL3480221 | 0.73 | CA2 (0.41) | CA2TPSAB1 | |
| SCHEMBL16666550 | 0.71 | TPSAB1 (0.31) | CA2TPSAB1 | |
| SCHEMBL16667292 | 0.70 | TPSAB1 (0.33) | CA2TPSAB1 | |
| SCHEMBL14931228 | 0.70 | CA2 (0.46) | CA2TPSAB1 | |
| SCHEMBL14931348 | 0.70 | TRPV4 (0.37) | — | |
| SCHEMBL16667420 | 0.70 | TPSAB1 (0.32) | CA2TPSAB1 | |
| SCHEMBL3483839 | 0.69 | TPSAB1 (0.32) | TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049200-B1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2015-04-29 | — | — | EP | disclosed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | CA2 440/4885TPSAB1 171/4885CYP2A6 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.